Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ben Tre Pharmaceutical JSCSTC:DBT -1.50%14 3-Year EPS without NRI Growth Rate is 0.00% as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 784 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 127550.89% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Ben Tre Pharmaceutical JSC (STC:DBT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ben Tre Pharmaceutical JSC 3-Year EPS without NRI Growth Rate Related Terms
STC:DBT vs ZTS, UTHR, VTRS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ben Tre Pharmaceutical JSC 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ben Tre Pharmaceutical JSC's 3-Year EPS without NRI Growth Rate falls into.
Ben Tre Pharmaceutical JSC 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a 3-Year EPS without NRI Growth Rate of 0.00% as of . 20. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 784 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's 3-Year EPS without NRI Growth Rate too high?
Ben Tre Pharmaceutical JSC's current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 784 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 784 companies for 3-Year EPS without NRI Growth Rate. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ben Tre Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ben Tre Pharmaceutical JSC's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current 3-Year EPS without NRI Growth Rate of 0.00%. The current 3-Year EPS without NRI Growth Rate is 0.00%. Ben Tre Pharmaceutical JSC's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current 3-Year EPS without NRI Growth Rate is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
14GF Score
Get the complete analysis for STC:DBT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBT has been successfully added to your 
